-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Short Interest in Elevation Oncology, Inc. (NASDAQ:ELEV) Drops By 10.4%
Short Interest in Elevation Oncology, Inc. (NASDAQ:ELEV) Drops By 10.4%
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) saw a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 44,000 shares, a decline of 10.4% from the November 15th total of 49,100 shares. Approximately 0.3% of the company's shares are sold short. Based on an average daily volume of 45,200 shares, the days-to-cover ratio is currently 1.0 days.
Wall Street Analyst Weigh In
ELEV has been the topic of several recent analyst reports. HC Wainwright reiterated a "buy" rating and issued a $7.50 target price on shares of Elevation Oncology in a report on Monday, September 19th. SVB Leerink lowered shares of Elevation Oncology from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $11.00 to $2.00 in a report on Monday, November 7th. Finally, JPMorgan Chase & Co. lowered shares of Elevation Oncology from a "neutral" rating to an "underweight" rating in a report on Thursday, November 10th.
Get Elevation Oncology alerts:Elevation Oncology Stock Performance
Shares of ELEV stock opened at $1.00 on Tuesday. The firm's 50 day moving average price is $1.00 and its 200-day moving average price is $1.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 7.29 and a current ratio of 7.29. Elevation Oncology has a one year low of $0.86 and a one year high of $6.87. The firm has a market cap of $23.30 million, a P/E ratio of -0.27 and a beta of 0.48.
Elevation Oncology (NASDAQ:ELEV – Get Rating) last issued its quarterly earnings data on Thursday, November 3rd. The company reported ($1.67) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.55). As a group, equities research analysts predict that Elevation Oncology will post -3.7 EPS for the current year.Institutional Investors Weigh In On Elevation Oncology
A number of hedge funds have recently added to or reduced their stakes in the business. Annandale Capital LLC acquired a new stake in Elevation Oncology during the 3rd quarter worth approximately $34,000. Renaissance Technologies LLC lifted its holdings in Elevation Oncology by 11.7% during the 3rd quarter. Renaissance Technologies LLC now owns 288,657 shares of the company's stock worth $326,000 after buying an additional 30,257 shares in the last quarter. Millennium Management LLC acquired a new stake in Elevation Oncology during the 2nd quarter worth approximately $30,000. Virtu Financial LLC acquired a new stake in Elevation Oncology during the 2nd quarter worth approximately $31,000. Finally, Kennedy Capital Management Inc. increased its position in shares of Elevation Oncology by 968.4% in the 2nd quarter. Kennedy Capital Management Inc. now owns 149,893 shares of the company's stock valued at $210,000 after purchasing an additional 135,863 shares during the last quarter. 74.04% of the stock is currently owned by institutional investors and hedge funds.
About Elevation Oncology
(Get Rating)
Elevation Oncology, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion.
See Also
- Get a free copy of the StockNews.com research report on Elevation Oncology (ELEV)
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) saw a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 44,000 shares, a decline of 10.4% from the November 15th total of 49,100 shares. Approximately 0.3% of the company's shares are sold short. Based on an average daily volume of 45,200 shares, the days-to-cover ratio is currently 1.0 days.
高地腫瘤公司(納斯達克代碼:ELIV-GET評級)看到空頭股數在11月份出現了大幅下降。截至11月30日,空頭股數共有44,000股,較11月15日的49,100股下跌10.4%。該公司約0.3%的股票被賣空。以日均成交量45,200股計算,目前天數與回補比率為1.0天。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
ELEV has been the topic of several recent analyst reports. HC Wainwright reiterated a "buy" rating and issued a $7.50 target price on shares of Elevation Oncology in a report on Monday, September 19th. SVB Leerink lowered shares of Elevation Oncology from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $11.00 to $2.00 in a report on Monday, November 7th. Finally, JPMorgan Chase & Co. lowered shares of Elevation Oncology from a "neutral" rating to an "underweight" rating in a report on Thursday, November 10th.
Elev一直是最近幾份分析師報告的主題。在9月19日星期一的一份報告中,HC Wainwright重申了買入評級,併發布了Elevation Oncology股票的7.50美元目標價。在11月7日週一的一份報告中,SVB Leerink將Elevation Oncology的股票評級從“跑贏大盤”下調至“市場表現”,並將該公司的目標價從11.00美元下調至2.00美元。最後,摩根大通公司在11月10日星期四的一份報告中將Elevation Oncology的股票評級從中性下調至減持。
Elevation Oncology Stock Performance
Elevation腫瘤學股票表現
Shares of ELEV stock opened at $1.00 on Tuesday. The firm's 50 day moving average price is $1.00 and its 200-day moving average price is $1.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 7.29 and a current ratio of 7.29. Elevation Oncology has a one year low of $0.86 and a one year high of $6.87. The firm has a market cap of $23.30 million, a P/E ratio of -0.27 and a beta of 0.48.
週二,Elev的股票開盤報1.00美元。該公司的50日移動均線價格為1.00美元,200日移動均線價格為1.21美元。該公司的負債權益比率為0.44,速動比率為7.29,流動比率為7.29。Elevation Oncology的一年低點為0.86美元,一年高位為6.87美元。該公司市值為2330萬美元,本益比為-0.27,貝塔係數為0.48。
Institutional Investors Weigh In On Elevation Oncology
機構投資者參與Elevation腫瘤學
A number of hedge funds have recently added to or reduced their stakes in the business. Annandale Capital LLC acquired a new stake in Elevation Oncology during the 3rd quarter worth approximately $34,000. Renaissance Technologies LLC lifted its holdings in Elevation Oncology by 11.7% during the 3rd quarter. Renaissance Technologies LLC now owns 288,657 shares of the company's stock worth $326,000 after buying an additional 30,257 shares in the last quarter. Millennium Management LLC acquired a new stake in Elevation Oncology during the 2nd quarter worth approximately $30,000. Virtu Financial LLC acquired a new stake in Elevation Oncology during the 2nd quarter worth approximately $31,000. Finally, Kennedy Capital Management Inc. increased its position in shares of Elevation Oncology by 968.4% in the 2nd quarter. Kennedy Capital Management Inc. now owns 149,893 shares of the company's stock valued at $210,000 after purchasing an additional 135,863 shares during the last quarter. 74.04% of the stock is currently owned by institutional investors and hedge funds.
一些對沖基金最近增持或減持了該業務的股份。Annandale Capital LLC在第三季度收購了Elevation Oncology的新股份,價值約3.4萬美元。文藝復興技術有限責任公司在第三季度增持了11.7%的Elevation Oncology股份。復興科技有限責任公司現在擁有288,657股該公司股票,價值326,000美元,上個季度又購買了30,257股。千禧管理公司在第二季度收購了Elevation Oncology價值約3萬美元的新股份。Virtu Financial LLC在第二季度收購了Elevation Oncology的新股份,價值約3.1萬美元。最後,肯尼迪資本管理公司在第二季度將其在Elevation Oncology的股票頭寸增加了968.4%。肯尼迪資本管理公司目前持有149,893股該公司股票,價值21萬美元,該公司在上個季度又購買了135,863股。74.04%的股票目前由機構投資者和對沖基金持有。
About Elevation Oncology
關於立面腫瘤學
(Get Rating)
(獲取評級)
Elevation Oncology, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion.
Elevation Oncology,Inc.是一家臨床階段的生物製藥公司,專注於開發治療美國基因組定義的患者群體中的癌症的療法。該公司的主導專案是Serbantumab,這是一種抗HER3的單抗,正處於Crestone第二階段試驗,用於治療含有neuRegin-1融合的晚期實體腫瘤。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Elevation Oncology (ELEV)
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
- 免費獲取StockNews.com關於高位腫瘤學(ELEV)的研究報告
- 如果馬斯克退出Twitter,特斯拉的股價會上漲嗎?
- 2023年值得關注的5個下跌但不是下跌的股票
- Chewy能否在2023年獲得兩位數的增長?
- 禮來公司預計將實現持久增長,儘管面臨眼前的挑戰
- Madrigal製藥公司的股票在一天內上漲了200%,原因如下
Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Elevation腫瘤學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Elevation Oncology和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧